title: An open study with reversible MAO-A inhibitors in complicated Parkinson's disease.
authors.affiliation: Mediterranean Institute of Neuroscience, Sanatrix, Pozzilli (IS), Italy.
authors.forename: S
authors.initials: S
authors.lastname: Ruggieri
authors.forename: G
authors.initials: G
authors.lastname: Fabbrini
authors.forename: L
authors.initials: L
authors.lastname: Bramante
authors.forename: F
authors.initials: F
authors.lastname: DePandis
authors.forename: F
authors.initials: F
authors.lastname: Stocchi
authors.forename: P
authors.initials: P
authors.lastname: Barbanti
authors.forename: L
authors.initials: L
authors.lastname: Vacca
authors.forename: M
authors.initials: M
authors.lastname: Manfredi
mesh_terms: D000978:Antiparkinson Agents / Q000627:therapeutic use; D001549:Benzamides / Q000009:adverse effects / Q000627:therapeutic use*; D018491:Dopamine Agonists / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008875:Middle Aged; D020912:Moclobemide; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D009069:Movement Disorders / Q000188:drug therapy / Q000209:etiology; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy*
chemical_list: D000978:Antiparkinson Agents; D001549:Benzamides; D018491:Dopamine Agonists; D008996:Monoamine Oxidase Inhibitors; D007980:Levodopa; D020912:Moclobemide